Advertisement

Psychopharmacology

, Volume 231, Issue 2, pp 319–325 | Cite as

Changes in pro-inflammatory cytokines and body weight during 6-month risperidone treatment in drug naïve, first-episode schizophrenia

  • Xueqin Song
  • Xiaoduo Fan
  • Xue Li
  • Wei Zhang
  • Jinsong Gao
  • Jingping Zhao
  • Amy Harrington
  • Douglas Ziedonis
  • Luxian Lv
Original Investigation

Abstract

Objective

The present study aimed to examine the changes in pro-inflammatory cytokines and body weight during 6-month risperidone treatment in drug naïve, first-episode schizophrenia.

Methods

Sixty-two drug naïve, first-episode schizophrenia (SZ group) and 60 healthy individuals (control group) were enrolled in the study. Serum interleukin-1β (IL-1β), interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α) levels, and body weight were measured at baseline for both groups, and repeated for the SZ group at five different time points during 6-month risperidone treatment.

Results

At baseline, serum IL-1β, IL-6, and TNF-α levels in the SZ group (53.28 ± 12.62, 33.98 ± 14.13, 50.08 ± 12.86 pg/mL, respectively) were significantly higher than those in the control group (23.49 ± 15.27, 15.53 ± 7.16, 32.12 ± 15.23 pg/mL, respectively) (p's < 0.001). Within the SZ group, serum IL-1β levels decreased significantly at 2 weeks (48.02 ± 16.00 pg/mL, p < 0.01) and 1 month (44.70 ± 16.63 pg/mL, p < 0.001), but then gradually increased at 2 months (48.49 ± 18.87 pg/mL), 3 months (50.59 ± 18.48 pg/mL) and 6 months (53.64 ± 16.22 pg/mL) to the levels comparable to baseline; serum IL-6 levels changed significantly over the course of treatment (p = 0.001), but reached the levels comparable to baseline at 6 months (37.13 ± 13.23 pg/mL); serum levels of TNF-α increased significantly at 3 months (55.02 ± 16.69 pg/mL, p < 0.01) and 6 months (58.69 ± 13.57 pg/mL, p < 0.001); steady and significant weight gain was observed at each follow-up time point (p's < 0.001), from 56.71 ± 9.25 kg at baseline to 62.72 ± 9.53 kg at 6 months.

Conclusions

Risperidone treatment is associated with changes in serum pro-inflammatory cytokines levels and weight. There is an initial anti-inflammatory effect that reduces with treatment, potentially due to its weight gain side effect.

Keywords

Schizophrenia Interleukin-1β Interleukin-6 Tumor necrosis factor-α Inflammation 

Notes

Acknowledgments

Funding for this study was provided by the National Natural Science Foundation of China (No.30971058 to X-QS; No.81071090to L-XL), the Natural Science Foundation of Henan (No.102300413208, 112300413226 to L-XL), and the Youth Fund of the First Affiliated Hospital of Zhengzhou University (to X-QS).

Financial disclosures

Dr. Fan has received research support or honoraria from Eli Lilly, AstraZeneca, Bristol-Myer-Squibb, Janssen, and Pfizer. Other authors report no competing interests.

Contributors

Dr. Song and Dr. Fan were responsible for the analysis and interpretation of the data for this paper. All authors contributed to the writing of the paper.

Conflict of interest

None of the authors has any actual or potential conflict of interest including any financial, personal, or other relationships with other people or organizations that could inappropriately influence, or be perceived to influence, their work as submitted in the uploaded material.

References

  1. Amrami-Weizman A, Maayan R, Gil-Ad I, Pashinian A, Fuchs C, Kotler M, Poyurovsky M (2013) The effect of reboxetine co-administration with olanzapine on metabolic and endocrine profile in schizophrenia patients. Psychopharmacology (Berlin) 230:23–27CrossRefGoogle Scholar
  2. Barzilay JI, Forsberg C, Heckbert SR, Cushman M, Newman AB (2006) The association of markers of inflammation with weight change in older adults: the Cardiovascular Health Study. Int J Obes (London) 30:1362–1367CrossRefGoogle Scholar
  3. Bushe CJ, Slooff CJ, Haddad PM, Karagianis JL (2013) Weight change by baseline BMI from 3-year observational data: findings from the Worldwide Schizophrenia Outpatient Health Outcomes Database. J Psychopharmacol 27:358–365, Oxford, EnglandPubMedCrossRefGoogle Scholar
  4. Chen C, Lu FC, Department of Disease Control Ministry of Health, P.R.C. (2004) The guidelines for prevention and control of overweight and obesity in Chinese adults. Biomed Environ Sci: BES 17:1–36PubMedGoogle Scholar
  5. Chen SL, Lee SY, Chang YH, Chen SH, Chu CH, Tzeng NS, Lee IH, Chen PS, Yeh TL, Huang SY, Yang YK, Lu RB, Hong JS (2012) Inflammation in patients with schizophrenia: the therapeutic benefits of risperidone plus add-on dextromethorphan. J Neuroimmune Pharm 7:656–664CrossRefGoogle Scholar
  6. Davey KJ, O'Mahony SM, Schellekens H, O'Sullivan O, Bienenstock J, Cotter PD, Dinan TG, Cryan JF (2012) Gender-dependent consequences of chronic olanzapine in the rat: effects on body weight, inflammatory, metabolic and microbiota parameters. Psychopharmacology (Berlin) 221:155–169CrossRefGoogle Scholar
  7. Drzyzga L, Obuchowicz E, Marcinowska A, Herman ZS (2006) Cytokines in schizophrenia and the effects of antipsychotic drugs. Brain Behav Immun 20:532–545PubMedCrossRefGoogle Scholar
  8. el-Mallakh RS, Suddath RL, Wyatt RJ (1993) Interleukin-1 alpha and interleukin-2 in cerebrospinal fluid of schizophrenic subjects. Prog Neuropsychopharmacol Biol Psychiatry 17:383–391PubMedCrossRefGoogle Scholar
  9. Fan X, Goff DC, Henderson DC (2007) Inflammation and schizophrenia. Expert Rev Neurother 7:789–796PubMedCrossRefGoogle Scholar
  10. Fan X, Borba CP, Copeland P, Hayden D, Freudenreich O, Goff DC, Henderson DC (2013) Metabolic effects of adjunctive aripiprazole in clozapine-treated patients with schizophrenia. Acta Psychiatr Scand 127:217–226PubMedCrossRefGoogle Scholar
  11. Fawzi MH, Fawzi MM, Fawzi MM, Said NS (2011) C-reactive protein serum level in drug-free male Egyptian patients with schizophrenia. Psychiatry Res 190:91–97PubMedCrossRefGoogle Scholar
  12. Fineberg AM, Ellman LM (2013) Inflammatory cytokines and neurological and neurocognitive alterations in the course of schizophrenia. Biol Psychiatry 73:951–966PubMedCrossRefGoogle Scholar
  13. Garver DL, Tamas RL, Holcomb JA (2003) Elevated interleukin-6 in the cerebrospinal fluid of a previously delineated schizophrenia subtype. Neuropsychopharmacology 28:1515–1520PubMedCrossRefGoogle Scholar
  14. Holz T, Thorand B, Doring A, Schneider A, Meisinger C, Koenig W (2010) Markers of inflammation and weight change in middle-aged adults: results from the prospective MONICA/KORA S3/F3 study. Obesity 18:2347–2353, Silver Spring, MdPubMedCrossRefGoogle Scholar
  15. Hotamisligil GS (2006) Inflammation and metabolic disorders. Nature 444:860–867PubMedCrossRefGoogle Scholar
  16. Jassim G, Skrede S, Vazquez MJ, Wergedal H, Vik-Mo AO, Lunder N, Dieguez C, Vidal-Puig A, Berge RK, Lopez M, Steen VM, Ferno J (2012) Acute effects of orexigenic antipsychotic drugs on lipid and carbohydrate metabolism in rat. Psychopharmacology (Berlin) 219:783–794CrossRefGoogle Scholar
  17. Kemp DE, Correll CU, Tohen M, Delbello MP, Ganocy SJ, Findling RL, Chang K (2013) Associations Among Obesity, Acute Weight Gain, and Response to Treatment with Olanzapine in Adolescent Schizophrenia. J Child Adolesc PsychopharmacolGoogle Scholar
  18. Kim YK, Myint AM, Verkerk R, Scharpe S, Steinbusch H, Leonard B (2009) Cytokine changes and tryptophan metabolites in medication-naive and medication-free schizophrenic patients. Neuropsychobiology 59:123–129PubMedCrossRefGoogle Scholar
  19. Leonard BE, Schwarz M, Myint AM (2012) The metabolic syndrome in schizophrenia: is inflammation a contributing cause? J Psychopharmacol 26:33–41, Oxford, EnglandPubMedCrossRefGoogle Scholar
  20. Licinio J, Seibyl JP, Altemus M, Charney DS, Krystal JH (1993) Elevated CSF levels of interleukin-2 in neuroleptic-free schizophrenic patients. Am J Psychiatry 150:1408–1410PubMedGoogle Scholar
  21. Lin A, Kenis G, Bignotti S, Tura GJ, De Jong R, Bosmans E, Pioli R, Altamura C, Scharpe S, Maes M (1998) The inflammatory response system in treatment-resistant schizophrenia: increased serum interleukin-6. Schizophr Res 32:9–15PubMedCrossRefGoogle Scholar
  22. Martinez-Gras I, Garcia-Sanchez F, Guaza C, Rodriguez-Jimenez R, Andres-Esteban E, Palomo T, Rubio G, Borrell J (2012) Altered immune function in unaffected first-degree biological relatives of schizophrenia patients. Psychiatry Res 200:1022–1025PubMedCrossRefGoogle Scholar
  23. Meyer JM, McEvoy JP, Davis VG, Goff DC, Nasrallah HA, Davis SM, Hsiao JK, Swartz MS, Stroup TS, Lieberman JA (2009) Inflammatory markers in schizophrenia: comparing antipsychotic effects in phase 1 of the clinical antipsychotic trials of intervention effectiveness study. Biol Psychiatry 66:1013–1022PubMedCentralPubMedCrossRefGoogle Scholar
  24. Miller BJ, Buckley P, Seabolt W, Mellor A, Kirkpatrick B (2011) Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects. Biol Psychiatry 70:663–671PubMedCrossRefGoogle Scholar
  25. Myint AM, Schwarz MJ, Verkerk R, Mueller HH, Zach J, Scharpe S, Steinbusch HW, Leonard BE, Kim YK (2011) Reversal of imbalance between kynurenic acid and 3-hydroxykynurenine by antipsychotics in medication-naive and medication-free schizophrenic patients. Brain Behav Immun 25:1576–1581PubMedCrossRefGoogle Scholar
  26. Na KS, Kim YK (2007) Monocytic, Th1 and th2 cytokine alterations in the pathophysiology of schizophrenia. Neuropsychobiology 56:55–63PubMedCrossRefGoogle Scholar
  27. Naudin J, Capo C, Giusano B, Mege JL, Azorin JM (1997) A differential role for interleukin-6 and tumor necrosis factor-alpha in schizophrenia? Schizophr Res 26:227–233PubMedCrossRefGoogle Scholar
  28. Nunes SO, Matsuo T, Kaminami MS, Watanabe MA, Reiche EM, Itano EN (2006) An autoimmune or an inflammatory process in patients with schizophrenia, schizoaffective disorder, and in their biological relatives. Schizophr Res 84:180–182PubMedCrossRefGoogle Scholar
  29. O'Brien SM, Scully P, Dinan TG (2008) Increased tumor necrosis factor-alpha concentrations with interleukin-4 concentrations in exacerbations of schizophrenia. Psychiatry Res 160:256–262PubMedCrossRefGoogle Scholar
  30. Odegaard JI, Chawla A (2013) Pleiotropic actions of insulin resistance and inflammation in metabolic homeostasis. Science 339:172–177PubMedCrossRefGoogle Scholar
  31. Ou JJ, Xu Y, Chen HH, Fan X, Gao K, Wang J, Guo XF, Wu RR, Zhao JP (2013) Comparison of metabolic effects of ziprasidone versus olanzapine treatment in patients with first-episode schizophrenia. Psychopharmacology (Berlin) 225:627–635CrossRefGoogle Scholar
  32. Pollmacher T, Hinze-Selch D, Mullington J (1996) Effects of clozapine on plasma cytokine and soluble cytokine receptor levels. J Clin Psychopharmacol 16:403–409PubMedCrossRefGoogle Scholar
  33. Potvin S, Stip E, Sepehry AA, Gendron A, Bah R, Kouassi E (2008) Inflammatory cytokine alterations in schizophrenia: a systematic quantitative review. Biol Psychiatry 63:801–808PubMedCrossRefGoogle Scholar
  34. Rapaport MH, McAllister CG, Pickar D, Tamarkin L, Kirch DG, Paul SM (1997) CSF IL-1 and IL-2 in medicated schizophrenic patients and normal volunteers. Schizophr Res 25:123–129PubMedCrossRefGoogle Scholar
  35. Ritchie SA, Connell JM (2007) The link between abdominal obesity, metabolic syndrome and cardiovascular disease. Nutr Metab Cardiovasc Dis: NMCD 17:319–326PubMedCrossRefGoogle Scholar
  36. Rudolf S, Peters M, Rothermundt M, Arolt V, Kirchner H (2002) The influence of typical and atypical neuroleptic drugs in the production of interleukin-2 and interferon-gamma in vitro. Neuropsychobiology 46:180–185PubMedCrossRefGoogle Scholar
  37. Runeson BS, Rich CL (1994) Diagnostic and Statistical Manual of Mental Disorders, 3rd ed. (DSM-III), adaptive functioning in young Swedish suicides. Ann Clin Psychiatry: Off J Am Acad Clin Psychiatr 6:181–183CrossRefGoogle Scholar
  38. Schattner A, Cori Y, Hahn T, Sirota P (1996) No evidence for autoimmunity in schizophrenia. J Autoimmun 9:661–666PubMedCrossRefGoogle Scholar
  39. Song XQ, Lv LX, Li WQ, Hao YH, Zhao JP (2009) The interaction of nuclear factor-kappa B and cytokines is associated with schizophrenia. Biol Psychiatry 65:481–488PubMedCrossRefGoogle Scholar
  40. Tateya S, Kim F, Tamori Y (2013) Recent advances in obesity-induced inflammation and insulin resistance. Front Endocrinol (Lausanne) 4:93Google Scholar
  41. Vasunilashorn S (2013) Retrospective reports of weight change and inflammation in the US National Health and Nutrition Examination Survey. J Obes 2013:601534PubMedCentralPubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2013

Authors and Affiliations

  • Xueqin Song
    • 1
    • 2
    • 3
  • Xiaoduo Fan
    • 3
  • Xue Li
    • 1
  • Wei Zhang
    • 1
  • Jinsong Gao
    • 1
  • Jingping Zhao
    • 4
  • Amy Harrington
    • 3
  • Douglas Ziedonis
    • 3
  • Luxian Lv
    • 2
    • 5
  1. 1.The First Affiliated Hospital/Zhengzhou UniversityZhengzhouChina
  2. 2.Henan Province Biological Psychiatry Key LaboratoryXinxiang Medical UniversityXinxiangChina
  3. 3.Psychotic Disorders ProgramUMass Memorial Medical Center/University of Massachusetts Medical SchoolWorcesterUSA
  4. 4.The Mental Health Institute of the Second Xiangya HospitalCentral South UniversityChangshaChina
  5. 5.Henan Province Mental HospitalThe Second Affiliated Hospital/Xinxiang Medical UniversityXinxiangChina

Personalised recommendations